GSK Spins Off A Hearing-Drug Firm | Chemical & Engineering News
Volume 89 Issue 35 | p. 17 | Concentrates
Issue Date: August 29, 2011

GSK Spins Off A Hearing-Drug Firm

Department: Business
News Channels: Biological SCENE
Keywords: pharmaceuticals, hearing loss, tinnitus

GlaxoSmithKline has taken a minority stake in Autifony Therapeutics, a spin-off of GSK’s early-stage hearing disorder assets. The investment firms Imperial Innovations and SV Life Sciences will each contribute roughly $8 million to the start-up. Autifony will focus on developing modulators of voltage-gated ion channels to treat hearing loss and tinnitus. It hopes to put its first compound into Phase I studies by early 2013.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment